


CAL-B accelerated novel synthetic protocols for 3,3'-arylidenebis-4-hydroxycoumarins and dimethyl ((substituted phenyl) (phenylamino)methyl) phosphonates

Published: 19 July 2021

Volume 47, pages 4497–4512, (2021) [Cite this article](#)

[Download PDF](#) ↓

Access provided by Dr. Babasaheb Ambedkar Marathwada University, Aurangabad



[Research on Chemical Intermediates](#)

[Aims and scope](#)

[Submit manuscript](#)

[Anusaya S. Chavan](#), [Arun S. Kharat](#), [Manisha R. Bhosle](#), [Sambhaji T. Dhumal](#) & [Ramrao A. Mane](#)



246 Accesses 4 Citations [Explore all metrics](#) →

Abstract


Green protocols for the syntheses of 3,3'-arylidenebis-4-hydroxycoumarins and dimethyl ((substituted phenyl) (phenylamino)methyl) phosphonates have been first time developed

using biocatalyst, CAL-B (lipase). These are carried at room temperature under stirring and are convenient and cost effective. The developed protocols are environmentally acceptable and are giving better to excellent yields of the titled products.

Graphic abstract




Similar content being viewed by others




Natural products inspired [3 + 2] cycloaddition enables efficient construction of...

Article | 28 May 2024



Multicomponent synthesis of 3-(1H-indol-3-yl)-2-phenyl-1H-imidazole

Article | 05 June 2024



Recent developments in synthetic chemistry and biological activities of pyrazole derivatives

Article | 09 August 2019

[Use our pre-submission checklist →](#)



Avoid common mistakes on your manuscript.

Introduction

Coumarins and α -amino phosphonates are gaining more importance as some of their derivatives have shown promising bioactivities. Coumarins are found naturally in various plants and are members of a class of heterocyclic compounds [1]. They are extensively employed as food and cosmetic additives [2], dye lasers [3,4,5] and gain stabilizing medium. They are found to possess anticoagulant, antibiotic, antitumor, anti-HIV, antihypertensive, analgesic, anti-inflammatory and anti-arrhythmia activities and are explored as precursor molecules in pharmaceutical industries [6,7,8,9,10,11,12,13]. Biscoumarins are vital organic compounds and have received considerable attention because of their broad spectrum of biological and interesting potential therapeutic activities. They often possess interesting pharmacological properties and act as antitumor, antibacterial [3,4,5,6,7,8], anticancer [9], urease and α -glucosidase inhibitory [10, 11], antifungal [12], and antiproliferative [13] agents. Dicoumarol and taxolin combination enhances synergistic inhibition of cell division of sea urchin embryos. These two compounds can be used in combination in order to reduce the high toxicity of taxol.

The distinctive nature of bioactive organophosphorus compounds has established their wide applicability in agricultural, medicinal, and industrial areas. α -Aminophosphonates are structural analogs of natural amino acids. They are considered as an important class of compounds with diverse and interesting biological activities [14,15,16,17,18,19]. Organophosphorus chemistry has provided valuable materials with potential biological activities of medicinal importance, and such products act as enzyme inhibitors [14], and are found to have HIV protease [15], antibiotic [16], herbicidal, fungicidal, insecticidal [17], plant growth regulating [18], antithrombotic [19], peptidases and proteases properties [20].

In view of these applications, several synthetic protocols have been reported to synthesize these compounds. Biscoumarins usually synthesized by carrying separately one-pot condensation of 4-hydroxycoumarins and aryl aldehydes in the presence of one of the

catalysts viz. glacial acetic acid [21], acetic acid anhydride [22, 23], iodine [24], silica-supported sodium hydrogen sulfate and indion 190 resin in toluene [25], ionic liquids [26], silica-supported preyssler nanoparticles [27], tetrabutyl ammonium bromide (TBAB) [28], microwave irradiation with silica-gel support [21, 29, 30], dodecyl benzene sulfonic acid (DBSA)MW [31], phospho sulfonic acid [32], CuO–CeO₂ nanocomposite [33], starch-sulfuric acid [34], LTNPs [35], MgO-NPs [36], BiVO₄-NPs [37], SiO₂-OSO₃H NPs [38], P₄VPy-CuO [39], magnetic nanoparticle catalyst TrBr/[Fe₃O₄@SiO₂@(CH₂)₃-ImSO₃H]Cl [40], IL@CNTs [41], Hnmp/ZnCl₃ [42], [Dabco-H][AcO] [43], [TMG][Ac] [44], RHA-SO₃H [45], KF-montmorillonite [46], and PS-Zn-anthra complex [47], and Mn(pbdo)₂Cl₂/MCM-41 [48].

Mostly practiced synthetic route for obtaining α -amino organophosphonates involves one-pot condensation of anilines, aryl aldehydes and di/trimethylphosphite. Efforts are also found to be directed to accelerate this condensation using various catalysts viz. lanthanide triflate, scandium tris(dodecyl sulfate) [49], samarium diiodide along with 4-Å molecular sieves [50], heterogeneous catalysts such as InCl₃ [51], TaCl₅-SiO₂ [52] (bromodimethyl) sulfonium bromide [53], LiClO₄ [54], montmorillonite KSF [55], ZrCl₄ [56], TiO₂ [57], alumina-supported reagents [58], ionic liquids [59], H₃PW₁₂O₄₀ [60], Amberlite-IR120 [61], and oxalic acid [62]. Recently, a synthesis of α -amino phosphonates from ferrocene-1-carboxaldehyde, anilines and diethyl phosphite under neat condition, catalyzed by KHSO₄, has been reported [63].

The above referred synthetic protocols are having one or other kind of drawbacks. These are not cost effective and need non-readily available and non-biodegradable heterogeneous/homogeneous catalysts. It is also reviewed that a little attention is found to be paid on the use of biocatalysts, particularly immobilized lipases to accelerate the above condensations leading to the titled compounds. Biocatalysts/enzymes are functional proteins and now a days they are used as safer and economic catalysts for carrying organic transformations leading to biodynamic compounds. Our group has explored the use of active Baker's yeast as a whole cell source of biocatalysts for carrying various cyclocondensations leading to biodynamic heterocycles [64,65,66,67,68,69,70,71,72].

Recently some of the lipases are also found to be used as catalyst for carrying cost effectively value-added organic transformations [73,74,75,76,77,78,79].

Lipases are employed for variety of reaction viz. esterifications [73], transesterifications [74], hydrolyses [75], Bayer–Villiger oxidations [76,77,78], and amidations [79]. Biocatalytic promiscuity of lipases has also been reported. Lipases are well explored as biocatalysts and do catalyze hydrolysis of water soluble carboxylic esters, particularly triglycerides and phospholipids. Among lipases *Candida Antarctica* Lipase B has been used as a biocatalyst in its pure form is as a immobilized CAL-B form to accelerate various organic reactions and biotransformations. Open and closed structures of this lipase have been thoroughly established by Benjamine et. al [80]. CAL-B is structurally similar to several other lipases and has a flexible lid. It is made up of 317 amino acids and is a member of α/β hydrolase-fold family. It consists of Serine, Histidine, and Asparic/Glutamic catalytical triad and has secondary alcoholic binding pocket. Usually these active sites viz. Serine, Histidine, Asparic/Glutamic amino acid residues participate to display catalytic behavior to accelerate the rates of organic/biotransformations [81]

Considering the dire need of establishing more convenient, cost-effective and eco-friendly synthetic protocols for the titled compounds, and significance of lipases as biocatalysts, here first time we have made an attempt to develop such synthetic protocols by carrying separately the above condensations in the presence of immobilized lipase, CAL-B, for obtaining the titled products 3,3'-arylidenebis-4-hydroxycoumarins and dimethyl ((substituted phenyl) (phenylamino)methyl) phosphonates conveniently and cost effectively.

Experimental

All the chemicals used were of laboratory grade. Lipase B *Candida Antarctica* immobilized on imobead 150 recombinant from yeast is procured from Sigma Alrich. Melting points of all the synthesized compounds were determined in open capillary tubes and are uncorrected. ^1H NMR spectra were recorded with a Bruker Avance 300 spectrometer operating at 400 MHz using $\text{DMSO}-d_6$ solvent and tetramethylsilane (TMS) as the internal standard and chemical shift in δ ppm. ^{13}C NMR spectra were recorded on Bruker Avance 75 MHz on Jeol. The purity of each compound was checked by TLC using silica-gel, 60F₂₅₄ aluminum sheets as adsorbent and visualization was accomplished by iodine/ultraviolet light.

Synthesis of 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-chromen-2-one) (3a)

Lipase, CAL-B (100 mg) was added to the reaction flask, containing ethanol (15 ml). Then, a mixture of benzaldehyde (1 gm/9.4 mmol) (1a) and 4-hydroxy coumarin (3.1 gm/18.8 mmol) (2) was added to the flask, and the whole reaction mass was stirred at rt. The progress of reaction was monitored by TLC using ethyl acetate: pet ether (2:8) as eluent. After stirring for 9 h, then ethyl acetate (3 × 10 ml) was added to the reaction mass and then stirred at room temperature for 10 min. and then filtered through Whatman paper. The solid residue remained on filter paper was further washed with 10 ml ethyl acetate. The obtained solid residue, CAL-B was dried and reused as a biocatalyst. Then, ethyl acetate and ethanol were removed from the collected filtrate under vacuum, and obtained crude residue remained was then crystallized using ethanol.

Similarly other derivatives of the series are prepared. The melting points and the isolated yields of the derivatives are recorded in Table 3. Melting points and spectral data of the 3,3'-arylidenebis-4-hydroxycoumarins (3a–l) are in good agreement with those reported in the literature [2, 15].

The scan copies of spectra of 3a are submitted herewith as a representative of the series (3a–l).

Synthesis of Dimethyl (phenyl(phenylamino)methyl)phosphonate (6a)

Benzaldehyde (0.5 gm/4.7 mmol) (1a) and aniline (0.438 gm/4.7 mmol) (4) were dissolved in acetonitrile (7 ml), and then solution was stirred for few minutes. Then, trimethylphosphite (0.585 gm/4.7 mmol) (5) and CAL-B, lipase (50 mg) were added to the solution and then reaction mixture was stirred at room temperature. Progress of reaction was monitored by TLC. After 40 min, water (10 ml) and ethyl acetate (30 ml) were added into the reaction mass and it was then stirred for 15 min and filtered. The residue recovered, CAL-B was dried and reused. The ethyl acetate layer was separated from filtrates and washed with water, and dried over anhydrous Na₂SO₄. The solvent ethyl acetate was removed under reduced pressure and obtained diethyl (phenyl(phenylamino)methyl) phosphonates (6a). The obtained crude products were then crystalized using ethanol. Similarly other derivatives of the series were prepared (6a–k). Melting points and isolated yields of the derivatives are recorded in Table 4.

The identity of the products was confirmed by ^1H and ^{13}C NMR, and HRMS, The spectral data in good agreement in those reported in the literature [[82](#), [83](#)].

Scan copies of spectra of 6b are provided as a representative of the series (6a–k).

Spectral data of compounds (3a–l)

3'-(Phenylmethylene)bis(4-hydroxy-2H-chromen-2-one) (3a)

^1H NMR (DMSO- d_6 , 300 MHz, δ ppm): 6.34 (s, 1H, –CH), 7.09–7.89 (m, 13H, Ar–H), 12.52 (s, 2H, 2OH). ^{13}C NMR (DMSO- d_6 , 75 MHz, δ ppm): 35.97, 91.01, 104.17, 115.80, 115.98, 116.35, 117.81, 123.19, 123.79, 123.90, 125.61, 126.71, 128.09, 128.54, 129.25, 131.95, 132.67, 132.82, 139.76, 152.20, 153.52, 161.88, 164.87, 165.17, 165.63. HRMS (ESI $^+$): (M + H) $^+$ calculated 413.1025, observed 413.1028.

3'-((4-Methoxyphenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3b)

^1H NMR (DMSO- d_6 , 300 MHz, δ ppm): 3.84 (s, 3H, OCH $_3$), 6.24 (s, 1H, –CH), 7.02–7.18 (m, 8H, Ar–H), 7.34–7.76 (m, 4H, Ar–H), 12.22 (s, 2H, 2OH). ^{13}C NMR (DMSO- d_6 , 75 MHz, δ ppm): 35.77, 56.98, 91.11, 104.23, 115.84, 115.58, 116.21, 117.68, 123.08, 123.56, 123.87, 125.48, 126.64, 128.01, 128.34, 129.15, 131.65, 132.57, 132.76, 139.45, 152.19, 153.34, 161.56, 164.45, 165.07, 165.52. HRMS (ESI $^+$): (M + H) $^+$ calculated 443.1131, observed 443.1029.

3'-(Tolylmethylene)bis(4-hydroxy-2H-chromen-2-one) (3c)

^1H NMR (CDCl $_3$, 300 MHz, δ ppm): 2.33 (s, 3H, CH $_3$), 6.06 (s, 1H, –CH), 7.08–8.05 (m, 12H, Ar–H), 11.30–11.49 (d, 2H, 2OH). ^{13}C NMR (CDCl $_3$, 75 MHz, δ ppm): 21.17, 36.08, 104.29, 105.96, 116.82, 124.58, 125.04, 126.57, 129.53, 132.25, 132.98, 136.67, 152.71, 164.75, 165.89, 167.04, 169.51. HRMS (ESI $^+$): (M + H) $^+$ calculated 427.1181, observed 427.1172.

3'-((4-Hydroxyphenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3d)

^1H NMR (DMSO- d_6 , 300 MHz, δ ppm): 4.98 (s, 1H, OH), 6.25 (s, 1H, –CH), 6.96–7.24 (m, 8H, Ar–H), 7.27–7.66 (m, 4H, Ar–H), 12.32 (s, 2H, 2OH). ^{13}C NMR (DMSO- d_6 , 75 MHz, δ ppm): 35.54, 91.32, 105.87, 115.65, 116.01, 116.37, 117.58, 121.47, 123.21, 123.87, 124.76, 126.65, 128.78, 128.92, 129.47, 131.49, 132.02, 132.94, 138.19, 152.45, 153.69, 161.08, 164.56, 165.69, 165.40.

HRMS (ESI⁺): (M + H)⁺ calculated 429.0974, observed 429.0832.

3'-((3-Bromophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3e)

¹H NMR (DMSO-*d*₆, 300 MHz, δ ppm): 6.44 (s, 1H, -CH), 7.18–7.42 (m, 8H, Ar-H), 7.55–8.06 (m, 4H, Ar-H), 12.67 (s, 2H, 2OH). ¹³C NMR (DMSO-*d*₆, 75 MHz, δ ppm): 36.02, 90.98, 104.64, 115.36, 115.57, 116.39, 117.65, 123.56, 123.83, 123.34, 125.46, 126.59, 127.54, 128.21, 129.49, 131.43, 132.78, 132.28, 139.54, 152.76, 153.21, 161.78, 164.23, 165.27, 165.57. HRMS (ESI⁺): (M + H)⁺ calculated 491.0130, observed 491.0028.

3'-((4-Fluorophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3f)

¹H NMR (CDCl₃, 300 MHz, δ ppm): 6.05 (s, 1H, -CH), 6.98–8.07 (m, 12H, Ar-H), 11.32–11.52 (d, 2H, 2OH). ¹³C NMR (CDCl₃, 75 MHz, δ ppm): 35.87, 104.14, 105.68, 115.59, 115.81, 116.58, 116.85, 117.06, 124.60, 125.15, 128.32, 128.40, 131.02, 131.05, 133.17, 152.49, 152.73, 160.69, 163.14, 164.80, 166.08, 167.02, 169.40. HRMS (ESI⁺): (M + H)⁺ calculated 431.0931, observed 431.0924.

3'-((4-Trifluoromethylphenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3g)

¹H NMR (DMSO-*d*₆, 300 MHz, δ ppm): 6.19 (s, 1H, -CH), 7.03–7.22 (m, 8H, Ar-H), 7.33–7.66 (m, 4H, Ar-H), 12.25 (s, 2H, 2OH). ¹³C NMR (DMSO-*d*₆, 75 MHz, δ ppm): 35.95, 91.09, 104.51, 115.46, 115.87, 116.89, 117.03, 123.36, 123.62, 123.89, 124.67, 126.56, 128.87, 128.87, 129.32, 130.76, 132.45, 132.76, 139.32, 152.48, 153.92, 161.23, 164.74, 166.37, 168.89. HRMS (ESI⁺): (M + H)⁺ calculated 481.0899, observed 481.0835.

3'-((4-Trifluoromethoxyphenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3h)

¹H NMR (DMSO-*d*₆, 300 MHz, δ ppm): 6.21 (s, 1H, -CH), 7.02–7.17 (m, 8H, Ar-H), 7.31–7.77 (m, 4H, Ar-H), 12.24 (s, 2H, 2OH). ¹³C NMR (DMSO-*d*₆, 75 MHz, δ ppm): 35.95, 91.76, 104.56, 115.43, 115.84, 116.65, 117.65, 123.20, 123.78, 123.87, 125.65, 126.52, 128.23, 128.34, 129.76, 131.65, 132.45, 132.79, 139.98, 152.56, 153.46, 161.72, 164.81, 165.63, 166.89. HRMS (ESI⁺): (M + H)⁺ calculated 497.0848, observed 497.0876.

3'-((4-Dimethylaminophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3i)

^1H NMR (DMSO- d_6 , 300 MHz, δ ppm): 3.09 (s, 6H, CH_3), 6.42 (s, 1H, $-\text{CH}$), 7.01–7.28 (m, 8H, Ar-H), 7.33–7.76 (m, 4H, Ar-H), 12.42 (s, 2H, 2OH). ^{13}C NMR (DMSO- d_6 , 75 MHz, δ ppm): 35.89, 50.23, 90.97, 105.52, 115.67, 116.21, 116.67, 117.38, 121.57, 123.50, 123.81, 125.42, 126.68, 128.39, 128.64, 129.78, 130.37, 132.49, 132.75, 139.59, 152.17, 153.72, 161.81, 163.78, 165.76, 167.41. HRMS (ESI $^+$): (M + H) $^+$ calculated 456.1447, observed 456.1356.

3'-((4-Nitrophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3j)

^1H NMR (CDCl_3 , 300 MHz, δ ppm): 6.12 (s, 1H, $-\text{CH}$), 7.26–8.20 (m, 12H, Ar-H), 11.35–11.56 (d, 2H, 2OH). ^{13}C NMR (CDCl_3 , 75 MHz, δ ppm): 36.72, 103.47, 104.96, 116.43, 116.92, 116.99, 124.05, 124.69, 125.34, 125.40, 127.76, 133.54, 143.55, 147.09, 152.52, 152.77, 165.01, 166.60, 167.17, 169.28. HRMS (ESI $^+$): (M + H) $^+$ calculated 458.0876, observed 458.0882.

3'-((4-Chlorophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3k)

^1H NMR (DMSO- d_6 , 300 MHz, δ ppm): 6.34 (s, 1H, $-\text{CH}$), 7.29–7.45 (m, 8H, Ar-H), 7.54–7.99 (m, 4H, Ar-H), 12.57 (s, 2H, 2OH). ^{13}C NMR (DMSO- d_6 , 75 MHz, δ ppm): 35.87, 91.56, 112.43, 115.53, 115.86, 116.71, 117.63, 123.58, 123.17, 123.49, 125.18, 126.53, 128.27, 128.83, 129.54, 131.76, 132.38, 132.76, 139.42, 152.45, 153.76, 161.98, 164.56, 165.37, 166.37. HRMS (ESI $^+$): (M + H) $^+$ calculated 447.0635, observed 447.0658.

3'-((2-Bromophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3l)

^1H NMR (DMSO- d_6 , 300 MHz, δ ppm): 6.44 (s, 1H, $-\text{CH}$), 7.21–7.45 (m, 8H, Ar-H), 7.52–8.06 (m, 4H, Ar-H), 12.67 (s, 2H, 2OH). ^{13}C NMR (DMSO- d_6 , 75 MHz, δ ppm): 35.92, 91.12, 104.43, 114.64, 115.79, 115.96, 116.91, 122.97, 123.45, 123.68, 124.89, 125.65, 128.76, 128.23, 129.45, 130.65, 131.32, 132.58, 139.71, 152.42, 153.64, 161.86, 164.09, 165.18, 165.45. HRMS (ESI $^+$): (M + H) $^+$ calculated 491.0130, observed 491.0028.

Spectral data of compounds (6a–k)

Dimethyl ((4-methoxyphenyl)(phenylamino)methyl)phosphonate (6b)

^1H NMR (CDCl_3 , 400 MHz, δ ppm): 3.50 (s, 3H, $-\text{OCH}_3$), 3.74 (s, 3H, $-\text{OCH}_3$), 3.77 (s, 3H, $-\text{OCH}_3$),

OCH₃), 4.72 (s, 1H, -CH), 4.79 (s, 1H, -NH), 6.58–7.40 (m, 9H, Ar-H).¹³C NMR (CDCl₃, 100 MHz, δ ppm): 53.93, 54.00, 54.45, 55.97, 114.12, 114.39, 114.41, 118.72, 127.54, 127.57, 129.09, 129.14, 129.37, 146.24, 146.39, 159.62. HRMS (ESI⁺): (M + H)⁺ calculated 322.1208, observed 322.1205.

Dimethyl (phenyl(phenylamino)methyl)phosphonate (6a)

¹H NMR (CDCl₃, 400 MHz, δ ppm): 3.46 (s, 3H, -OCH₃), 3.75 (s, 3H, -OCH₃), 4.67–4.71 (d, 1H, -CH), 4.78 (s, 1H, -NH), 6.59–7.49 (m, 10H, Ar-H).¹³C NMR (CDCl₃, 100 MHz, δ ppm): 54.05, 55.14, 56.64, 114.09, 118.76, 127.98, 128.03, 128.29, 128.92, 129.40, 133.19, 135.78, 135.80, 146.21, 146.36. HRMS (ESI⁺): (M + H)⁺ calculated, 292.1102, observed, 292.1068.

Dimethyl (4-tolyl)(phenylamino)methyl)phosphonate (6c)

¹H NMR (CDCl₃, 400 MHz, δ ppm): 2.65 (s, 3H, -CH₃), 3.53 (s, 3H, -OCH₃), 3.78 (s, 3H, -OCH₃), 4.77 (s, 1H, -CH), 4.84 (s, 1H, -NH), 6.46–7.71 (m, 9H, Ar-H).¹³C NMR (CDCl₃, 100 MHz, δ ppm): 23.59, 54.08, 55.32, 56.62, 115.62, 118.76, 127.87, 128.52, 128.86, 128.92, 128.97, 129.42, 130.18, 135.67, 146.38, 146.84. HRMS (ESI⁺): (M + H)⁺ calculated, 306.1259, observed, 306.1168.

Dimethyl (4-hydroxyphenyl)(phenylamino)methyl)phosphonate (6d)

¹H NMR (CDCl₃, 400 MHz, δ ppm): 3.44 (s, 3H, -OCH₃), 3.73 (s, 3H, -OCH₃), 4.79–4.86 (d, 1H, -CH), 4.91 (s, 1H, -NH), 5.46 (s, 1H, OH), 6.61–7.52 (m, 9H, Ar-H).¹³C NMR (CDCl₃, 100 MHz, δ ppm): 53.97, 54.34, 56.74, 114.67, 118.59, 127.24, 128.74, 128.78, 129.32, 129.69, 130.53, 133.67, 135.39, 135.47, 146.98. HRMS (ESI⁺): (M + H)⁺ calculated, 308.1051, observed, 308.0682.

Dimethyl (3-Bromophenyl)(phenylamino)methyl)phosphonate (6e)

¹H NMR (CDCl₃, 400 MHz, δ ppm): 3.43 (s, 3H, -OCH₃), 3.78 (s, 3H, -OCH₃), 4.77–4.83 (d, 1H, -CH), 4.87 (s, 1H, -NH), 6.67–7.72 (m, 9H, Ar-H).¹³C NMR (CDCl₃, 100 MHz, δ ppm): 53.89, 54.23, 56.16, 114.67, 118.24, 127.82, 128.59, 128.12, 128.87, 128.36, 128.58, 128.69, 135.86, 135.59, 146.79. HRMS (ESI⁺): (M + H)⁺ calculated, 370.0207, observed, 370.0158.

Dimethyl (4-Fluorophenyl)(phenylamino)methyl)phosphonate (6f)

^1H NMR (CDCl_3 , 400 MHz, δ ppm): 3.28 (s, 3H, $-\text{OCH}_3$), 3.46 (s, 3H, $-\text{OCH}_3$), 4.38–4.73 (d, 1H, $-\text{CH}$), 4.86 (s, 1H, $-\text{NH}$), 6.98–7.53 (m, 9H, Ar–H). ^{13}C NMR (CDCl_3 , 100 MHz, δ ppm): 54.01, 55.39, 56.57, 115.37, 118.68, 127.38, 128.72, 128.49, 128.42, 128.58, 130.27, 135.46, 135.72, 146.35, 146.64. HRMS (ESI^+): ($\text{M} + \text{H}$) $^+$ calculated, 310.1008, observed, 310.1068.

Dimethyl ((phenylamino)(4-(trifluoromethyl)phenyl)methyl)phosphonate (6g)

^1H NMR (CDCl_3 , 400 MHz, δ ppm): 3.55 (s, 3H, $-\text{OCH}_3$), 3.77 (s, 3H, OCH_3), 4.83 (s, 1H, $-\text{CH}$), 4.89 (s, 1H, $-\text{NH}$), 6.55–6.75 (m, 5H, Ar–H), 7.10–7.62 (m, 4H, Ar–H). ^{13}C NMR (CDCl_3 , 100 MHz, δ ppm): 53.96, 54.96, 56.45, 114.04, 119.20, 120.13, 122.84, 125.88, 125.91, 128.33, 129.53, 130.61, 130.96, 140.27, 145.80, 145.94. HRMS (ESI^+): ($\text{M} + \text{H}$) $^+$ calculated, 360.0976, observed, 360.0976.

Dimethyl ((phenylamino)(4-(trifluoromethoxy)phenyl)methyl)phosphonate (6h)

^1H NMR (CDCl_3 , 400 MHz, δ ppm): 3.53 (s, 3H, OCH_3), 3.71 (s, 3H, OCH_3), 4.78 (s, 1H, $-\text{CH}$), 4.83 (s, 1H, $-\text{NH}$), 6.56–7.26 (m, 5H, Ar–H), 7.49–7.52 (d, 4H, Ar–H). ^{13}C NMR (CDCl_3 , 100 MHz, δ ppm): 53.93, 54.51, 56.02, 114.03, 119.09, 119.34, 121.33, 121.90, 129.33, 129.39, 129.51, 134.61, 134.64, 145.90, 146.04, 149.17. HRMS (ESI^+): ($\text{M} + \text{H}$) $^+$ calculated 376.0925, observed 376.0921.

Dimethyl ((4-(dimethylamino)phenyl)(phenylamino)methyl)phosphonate (6i)

^1H NMR (CDCl_3 , 400 MHz, δ ppm): 3.46 (s, 3H, OCH_3), 3.75 (s, 3H, OCH_3), 4.77–4.83 (d, 1H, $-\text{CH}$), 6.59–7.49 (m, 10H, Ar–H). ^{13}C NMR (CDCl_3 , 100 MHz, δ ppm): 43.69, 54.02, 55.37, 56.76, 114.13, 118.47, 127.78, 128.43, 128.57, 128.73, 128.85, 129.29, 133.45, 135.76, 146.27, 146.69. HRMS (ESI^+): ($\text{M} + \text{H}$) $^+$ calculated, 335.1524, observed, 335.1481.

Dimethyl (4-nitrophenyl)(phenylamino)methyl)phosphonate (6j)

^1H NMR (CDCl_3 , 400 MHz, δ ppm): 3.48 (s, 3H, OCH_3), 3.65 (s, 3H, OCH_3), 4.69 (s, 1H, $-\text{CH}$), 4.86 (s, 1H, $-\text{NH}$), 6.98–7.76 (m, 9H, Ar–H). ^{13}C NMR (CDCl_3 , 100 MHz, δ ppm): 53.72, 54.21, 56.73, 114.64, 118.86, 127.46, 128.38, 128.57, 128.38, 128.48, 129.51, 130.53, 135.49, 146.54, 146.38. HRMS (ESI^+): ($\text{M} + \text{H}$) $^+$ calculated, 337.0925, observed, 337.0798.

Dimethyl (4-chlorophenyl)(phenylamino)methyl)phosphonate (6k)

^1H NMR (CDCl_3 , 400 MHz, δ ppm): 3.52 (s, 3H, $-\text{OCH}_3$), 3.69 (s, 3H, $-\text{OCH}_3$), 4.71 (s, 1H, $-\text{CH}$), 4.82 (s, 1H, $-\text{NH}$), 6.75–7.89 (m, 9H, Ar-H). ^{13}C NMR (CDCl_3 , 100 MHz, δ ppm): 53.99, 54.08, 56.64, 114.53, 118.65, 127.81, 128.49, 128.85, 128.97, 129.13, 129.67, 130.82, 135.58, 146.79, 146.93. HRMS (ESI⁺): (M + H)⁺ calculated, 326.0713, observed, 326.0687.

Results and discussion

In view to optimize reaction conditions, we separately carried the condensations of a) benzaldehyde (1a) (1 gm/9.4 mmol), and 4-hydroxy coumarin (2) (3.1 gm/18.8 mmol), and b) benzaldehyde (1a), (0.5 gm/4.7 mmol), aniline (4) (0.438 gm/4.7 mmol), and trimethyl phosphite (5) (0.584 gm/4.7 mmol) as model reactions in the presence of CAL-B for obtaining 3,3'-((phenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3a) and dimethyl (phenyl(phenylamino)methyl)phosphonate (6a), respectively, by varying the amounts of CAL-B, reaction temperature and solvents and the observed results are incorporated in Tables [1](#) and [2](#).

Table 1 Effect of different reaction conditions on the isolated yields of 3,3'-((phenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) (3a)^a


Table 2 Effect of different reaction conditions on the isolated yields of dimethyl (phenyl(phenylamino)methyl)phosphonate (6a)^a

It was observed (Table [1](#)) that a model reaction when carried using benzaldehyde (1a) (1 gm/9.4 mmol), and 4-hydroxy coumarin (2) (3.1 gm/18.8 mmol), in ethanol (15 ml) in the presence of CAL-B (100 mg) at room temperature gave 90% yield within 9 h and hence considered these reaction conditions as optimal conditions for conducting the condensation. It was also noted (Table [2](#)) that the other multicomponent reaction when performed using

benzaldehyde (1a), (500 mg/4.7 mmol), aniline (4) (0.438 gm/4.7 mmol), and trimethyl phosphite (5) (0.585 gm/4.7 mmol) in acetonitrile (7 ml) in the presence of CAL-B at room temperature gave dimethyl (phenyl(phenylamino)methyl)phosphonate (6a) with 89% yield within 35 min. These reaction conditions are chosen as optimal conditions for this kind of condensation reaction for getting 6a–k. It was also observed that the CAL-B retained its potential catalytic activity even after its first use and found to be reusable. The details of its isolation and reuse have been incorporated in experimental procedure.

With these inspiring observations, we carried the synthesis of substituted 3,3'-arylidenebis-4-hydroxycoumarins (3a-l) (Scheme 1) and dimethyl ((substituted phenyl) (phenylamino)methyl) phosphonates (6a-k) (Scheme 2) using the above-optimized conditions and obtained better to excellent yields of the titled products. Physical data are summarized in Tables 3 and 4. All the synthesized compounds are known/reported and their physical constants and spectral data are in good agreement with those reported in the literature [2, 15, 82, 83].


Scheme 1



Synthesis of substituted 3,3'-arylidenebis-4-hydroxycoumarins (3a-l)

Scheme 2





Synthesis of dimethyl ((substituted phenyl) (phenylamino)methyl) phosphonates (6a-k)


Table 3 Physical data of substituted 3,3'-arylidenebis-4-hydroxycoumarins (3a-l)^a

Table 4 Physical data of dimethyl ((substituted phenyl) (phenylamino)methyl) phosphonates (6a-k)^a

It seems from the results recorded in Tables [1](#) and [2](#) that the condensations under reference are not found to be run satisfactorily in the absence of CAL-B, lipase and it is also observed that in the presence of lipase both the type of condensation are found to undergo rapidly, yielding reaction products at rt with better to excellent yields. Therefore, it is confirmed that lipase is displaying its catalytic role in both the condensations through the active amino acid residues. The plausible mechanism of these two types of condensations leading to titled products 3,3'-arylidenebis-4-hydroxycoumarins and dimethyl ((substituted phenyl) (phenylamino)methyl) phosphonates in presence of CAL-B has been depicted in Schemes [3](#) and [4](#).


Scheme 3





Scheme 4







Plausible mechanism for the synthesis of Dimethyl (phenyl(phenylamino)methyl)phosphonate 6a)

Efficient recovery and reusability of the catalyst are the valuable advantages in modern catalysis research and green chemistry. In this respect, the recovery and reusability of CAL-B were investigated for the model reactions. Consequently, the model reactions were performed. After completion of reaction, ethyl acetate was added in the reaction mixture and CAL-B was easily separated from the product by simple filtration. The obtained solid residue, CAL-B was washed with ethyl acetate and reused for next three consecutive cycles for the synthesis of 3a. As shown in the recyclability graph of catalytic efficiency of CAL-B, the isolated yields were almost similar until the third recycling (Fig. 1). Only a slight decrease in the yield of the desired product 3a, was noticed.

Fig. 1





Recycle and recovery of CAL-B and its effect on yield of (3a)

Conclusion

First time an environmentally accepted, versatile, and efficient CAL-B catalyzed synthetic protocols have been developed for obtaining high yields of the 3,3'-arylidene bis-4-hydroxycoumarins and diethyl(phenyl (phenylamino)methyl) phosphonates. Catalyst lipase, CAL-B used here is biodegradable and cost-effective. These condensations leading to the title products, 3,3'-arylidene bis-4-hydroxycoumarins and diethyl(phenyl (phenylamino)methyl) phosphonates occur at room temperature in ethanol and in acetonitrile, respectively. Thus, we have opened up a new possibility for the synthesis of various heterocycles derivatives using CAL-B as catalyst. The protocols have nontedious workup in conducting and isolation of the products.

References

1. J. Hinman, H. Hoeksema, E.L. Caron, W.G. Jackson, *J. Am. Chem. Soc.* 78, 1072 (1956)

[Article](#) [CAS](#) [Google Scholar](#)

2. H. Mehrabi, H. Abusaidi, *J. Iran. Chem. Soc.* 7, 890 (2010)

[Article](#) [CAS](#) [Google Scholar](#)

3. E.A. Abu-Gharib, R.M. EL-Khatib, L.A.E. Nassr, A.M. Abu-Dief, J. Kore. Chem. Soc. 55(3), 346 (2011)

[Article](#) [CAS](#) [Google Scholar](#)

4. E.A. Abu-Gharib, R.M. El-Khatib, L.A.E. Nassr, A.M.R. Abu-Dief, J. Gen. Chem. 84(3), 578 (2014)

[Article](#) [CAS](#) [Google Scholar](#)

5. E.A. Abu-Gharib, R.M. EL-Khatib, L.A.E. Nassr, A.M. Abu-Dief, J. King Saud Univ-Sci. 27(1), 54 (2015)

[Article](#) [Google Scholar](#)

6. J. Li, Y.P. Sui, J.J. Xin, X.L. Du, J.T. Li, H.R. Huo, H. Ma, W.H. Wang, H. Zhou, Y.H.D. Zhan, Z.J. Wang, C. Li, F. Sui, X. Li, Bioorg. Med. Chem. Lett. 25, 5520 (2015)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

7. J. Li, Z. Hou, F. Li, Z.D. Zhang, Y. Zhou, X. Luo, X.M.K. Li, J. Mol. Struct. 107531, 509 (2014)

[Article](#) [CAS](#) [Google Scholar](#)

8. Y.P. Sui, H.R. Huo, J.J. Xin, J. Li, X. Li, J.X.L. Du, H. Ma, H.Y. Zhou, H.D. Zhan, Z.J. Wang, C. Li, F. Sui, M.K. Li, Molecules 20, 17614 (2015)

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

9. J.J. Xin, J. Li, Z.D. Zhang, X.B. Hu, M.K. Li, J. Mol. Struct. 1084, 200 (2015)

[Article](#) [CAS](#) [Google Scholar](#)

10. K.M. Khan, S. Iqbal, M.A. Lodhi, G.M. Maharvi, Z. Ullah, M.I. Choudhary, A. Rahman, S. Perveen, Bioorg. Med. Chem. 12, 1963 (2004)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

11. K.M. Khan, F. Rahim, A. Wadood, N. Kosar, M. Taha, S. Lalani, A. Khan, M.I. Fakhri, M. Junaid, W. Rehman, M. Khan, S. Perveen, M. Sajid, M.I. Choudhary, Eur. J. Med. Chem. 81, 245 (2014)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

12. Z.N. Siddiqui, M.T.N. Musthafa, A. Ahmad, A.U. Khan, Arch. Pharm. 344, 394 (2011)

[Article](#) [CAS](#) [Google Scholar](#)

13. I. Kostova, G. Momekov, Eur. J. Med. Chem. 41, 717 (2006)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

14. M. Kidwai, V. Bansal, P. Mothsra, S. Saxena, R.K. Somvanshi, S. Dey, T.P. Singh, J. Mol. Cat. A Chem. 268, 76 (2007)

[Article](#) [CAS](#) [Google Scholar](#)

15. V. Padalkara, K. Phatangarea, S. Takaleb, R. Pisalb, A. Chaskar, J. Saudi. Chem. Soc. 19, 42 (2015)

[Article](#) [Google Scholar](#)

16. J.M. Khurana, S. Kumar, *Monatsh. Chem.* 141, 561 (2010)

[Article](#) [CAS](#) [Google Scholar](#)

17. M.M. Heravia, F. Nahavandi, S. Sadjadi, H.A. Oskooie, F.F. Bamoharram, *Syn. Commu.* 40, 498 (2010)

[Article](#) [CAS](#) [Google Scholar](#)

18. J.M. Khurana, S. Kumar, *Tetrahedron Lett.* 50, 4125 (2009)

[Article](#) [CAS](#) [Google Scholar](#)

19. S. Kadir, A.A. Dar, K.Z. Khan, *Synth. Comm.* 38, 3490 (2008)

[Article](#) [CAS](#) [Google Scholar](#)

20. R. Okenne, R.D. Thomes, *Coumarins: Biology Application and Modes of Action* (Wiley, Chichester, 1997)

[Google Scholar](#)

21. I. Manolova, N.D. Danchev, *Arch. Pharm. Pharm. Med. Chem.* 332, 243 (1999)

[Article](#) [Google Scholar](#)

22. H. Madari, D. Panda, L. Wilson, R. Jacobs, *Cancer. Res.* 63, 1214 (2003)

[CAS](#) [PubMed](#) [Google Scholar](#)

23. J.N. Sangshetti, N.D. Kokare, D.B. Shinde, *Green Chem. Lett. and Rev.* 2(4), 233 (2009)

[Article](#) [CAS](#) [Google Scholar](#)

24. N. Hamdia, M.C. Puertab, P. Valerga, Eur. J. Med. Chem. 43, 2541 (2008)

[Article](#) [CAS](#) [Google Scholar](#)

25. K. Tabatabaeian, H. Heidari, A. Khorshidi, M. Mamaghani, N.O. Mahmoodi, J. Serb. Chem. Soc. 77, 407 (2012)

[Article](#) [CAS](#) [Google Scholar](#)

26. F. Shirini, M. Abedini, S.A. Kiaroudi, Phosph. Sul. Sili. Relat. Elem. 189, 1279 (2014)

[Article](#) [CAS](#) [Google Scholar](#)

27. B. Karmakar, A. Nayak, J. Banerji, Tetrahedron Lett. 53, 4343 (2012)

[Article](#) [CAS](#) [Google Scholar](#)

28. A.R. Kiasat, L. Hemat-Alian, Res. Chem. Intermed. 41, 873 (2015)

[Article](#) [CAS](#) [Google Scholar](#)

29. J. Albadi, A. Mansournezhad, S. Salehnasab, Res. Chem. Intermed. 41, 5713 (2015)

[Article](#) [CAS](#) [Google Scholar](#)

30. F. Shirini, A. Fallah-Shojaei, L. Samavi, M. Abedini, RSC Adv. 6, 48469 (2016)

[Article](#) [CAS](#) [Google Scholar](#)

31. M. Zarei, M.A. Zolfigol, A.R. Moosavi-Zare, E. Noroozizadeh, J. Irani. Chem. Soci. 14, 2187 (2017)
[Article](#) [CAS](#) [Google Scholar](#)
32. B. Mayank, P.K. Kaur Billing, N. Agnihotri, N. Kaur, D.O. Singh, A.C.S. Jang, Sust. Chem. Eng. 6, 3714 (2018)
[Article](#) [CAS](#) [Google Scholar](#)
33. F. Abbasi, N. Azizi, M. Abdoli-Senejani, J. Iran. Chem. Soci. 14, 2097 (2017)
[Article](#) [CAS](#) [Google Scholar](#)
34. C. Yang, W.Q. Su, D.Z. Xu, RSC Adv. 6, 99656 (2016)
[Article](#) [CAS](#) [Google Scholar](#)
35. A. Zhu, M. Wang, L. Li, J. Wang, RSC Adv. 5, 73974 (2015)
[Article](#) [CAS](#) [Google Scholar](#)
36. M. Seddighi, F. Shirini, M. Mamaghani, RSC Adv. 3, 24046 (2013)
[Article](#) [CAS](#) [Google Scholar](#)
37. M.S. Lamba, J.K. Makrandi, J. Chem. Res. 10, 585 (2007)
[Google Scholar](#)
38. S. Ghosh, P. Mondal, D. Das, K. Tuhina, S.M. Islam, J. Org. Chem. 866, 1 (2018)

[Article](#) [CAS](#) [Google Scholar](#)

39. M.M. Heravi, M. Daraie, Res. Chem. Intermed. 42, 2979 (2015)

[Article](#) [CAS](#) [Google Scholar](#)

40. Y. Fu, Z. Lu, K. Fang, X. He, H. Huang, Y. Hu, Bioorg. Med. Chem. Lett. 29, 1236 (2019)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

41. M.C. Allen, W. Fuhrer, B. Tuck, R. Wade, J.M. Wood, J. Med. Chem. 32, 1652 (1989)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

42. A. Peyman, W. Stahl, K. Wagner, D. Ruppert, K.H. Budt, Bioorg. Med. Chem. Lett. 4, 2601 (1994)

[Article](#) [CAS](#) [Google Scholar](#)

43. F.R. Atherton, C.H. Hassal, R.W. Lambert, J. Med. Chem. 29, 29 (1986)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

44. L. Maier, H. Spoerri, Phosph. Sul. Sili. Relat. Elem. 61, 69 (1991)

[Article](#) [CAS](#) [Google Scholar](#)

45. J. Emsley, D. Hall, The Chemistry of Phosphorous; (Harper & Row: London, 1976), 494

46. J.H. Meyer, P.A. Barlett, J. Am. Chem. Soc. 120(19), 4600 (1998)

[Article](#) [CAS](#) [Google Scholar](#)

47. D.J. Miller, S.M. Hammond, D. Anderluzzi, T.D.H. Bugg, J. Chem. Soc. Perkin Trans. 1, 131 (1998)

[Article](#) [Google Scholar](#)

48. K. Manabe, S. Kobayashi, Chem. Commun. 8, 669 (2000)

[Article](#) [Google Scholar](#)

49. F. Xu, Y. Luo, M. Deng, Q. Shen, Eur. J. Org. Chem. 35(15), 4728 (2003)

[Article](#) [CAS](#) [Google Scholar](#)

50. B.C. Ranu, A. Hajra, J. Jana, Org. Lett. 1, 1141 (1999)

[Article](#) [CAS](#) [Google Scholar](#)

51. S. Chandrasekhar, S. Jaya Prakash, V. Jagadeshwar, C. Narsihmula, Tetrahedron Lett. 42, 5561 (2001)

[Article](#) [CAS](#) [Google Scholar](#)

52. S. Kudrimoti, V.B. Rao, Tetrahedron Lett. 46, 1209 (2005)

[Article](#) [CAS](#) [Google Scholar](#)

53. A. Heydari, M. Zarei, R. Alijanianzadeh, H. Tavakol, Tetrahedron Lett. 42, 3629 (2001)

[Article](#) [CAS](#) [Google Scholar](#)

54. J.S. Yadav, B.V.S. Reddy, C. Madan, *Synlett* 7, 1131 (2001)

[Article](#) [Google Scholar](#)

55. J.S. Yadav, B.V.S. Reddy, S. Raj, K.B. Reddy, A.R. Prasad, *Synthesis* 15, 2277 (2001)

[Article](#) [Google Scholar](#)

56. B. Kaboudin, R. Nazari, *Tetrahedron Lett.* 42, 8211 (2001)

[Article](#) [CAS](#) [Google Scholar](#)

57. J.S. Yadav, B.V.S. Reddy, P. Sreedhar, *Green Chem.* 4, 436 (2002)

[Article](#) [CAS](#) [Google Scholar](#)

58. A. Heydari, H. Hamed, M. Pourayoubi, *Catal. Commun.* 8, 1224 (2007)

[Article](#) [CAS](#) [Google Scholar](#)

59. S.M. Vahdat, R. Baharfar, M. Tajbakhsh, A. Heydari, S.M. Baghbanian, S. Khaksar, *Tetrahedron Lett.* 49, 6501 (2008)

[Article](#) [CAS](#) [Google Scholar](#)

60. M. Hosseini-Sarvari, *Tetrahedron* 64, 5459 (2008)

[Article](#) [CAS](#) [Google Scholar](#)

61. P. Thirumurugan, A.N. Kumar, N.S. Priya, D. Muralidaran, P.T. Perumal, *Tetrahedron Lett.* 51, 5708 (2010)

[Article](#) [CAS](#) [Google Scholar](#)

62. A.K. Bhattacharya, C.K. Rana, *Tetrahedron Lett.* 49, 2598 (2008)

[Article](#) [CAS](#) [Google Scholar](#)

63. P. Anastas, J. Warner, *Green Chemistry: Theory and Practice* Oxford University Press, New York and references cited therein, (1998)

64. U.R. Pratap, DV. Jawale, R.A. Waghmare, D.L. Lingampalle, R.A. Mane, *New J. Chem.* 35, 49 (2011)

[Article](#) [CAS](#) [Google Scholar](#)

65. U.R. Pratap, J.R. Mali, DV. Jawale, R.A. Mane, *Tetrahedron Lett.* 50, 1352 (2009)

[Article](#) [CAS](#) [Google Scholar](#)

66. U.R. Pratap, DV. Jawale, M.R. Bhosle, R.A. Mane, *Tetrahedron Lett.* 52, 1689 (2011)

[Article](#) [CAS](#) [Google Scholar](#)

67. U.R. Pratap, DV. Jawale, P.D. Netankar, R.A. Mane, *Tetrahedron Lett.* 52, 5817 (2011)

[Article](#) [CAS](#) [Google Scholar](#)

68. U.R. Pratap, DV. Jawale, B.S. Londhe, R.A. Mane, *J. Mol. Cat. B Enzym.* 68, 94 (2011)

[Article](#) [CAS](#) [Google Scholar](#)

69. L.D. Khillare, U.R. Pratap, M.R. Bhosle, S.T. Dhumal, M.B. Bhalerao, R.A. Mane, *Res.*

Chem. Intermed. 43, 4327 (2017)

[Article](#) [CAS](#) [Google Scholar](#)

70. A.S. Chavan, A.S. Kharat, M.R. Bhosle, R.A. Mane, Synth. Commun. 47(19), 1777 (2017)

[Article](#) [CAS](#) [Google Scholar](#)

71. A.S. Chavan, A.S. Kharat, M.R. Bhosle, S.T. Dhumal, R.A. Mane, Synth. Commun. 51(13), 1963 (2021)

[CAS](#) [Google Scholar](#)

72. A.S. Chavan, A.S. Kharat, M.R. Bhosle, R.A. Mane, Heter. commun. 24(2), 103 (2018)

[Article](#) [CAS](#) [Google Scholar](#)

73. M.T. Reetz, Curr. Opin. Chem. Biol. 6, 145 (2002)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

74. I. Alfonso, V. Gotor, Chem. Soc. Rev. 33, 201 (2004)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

75. V. Gotor, Bioorg. Med. Chem. 7, 2189 (1999)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

76. A. Ghanem, Tetrahedron 63, 1721 (2007)

[Article](#) [CAS](#) [Google Scholar](#)

77. F. Hasan, A.A. Shah, A. Hameed, Enzyme Microb. Technol. 39, 235 (2006)

[Article](#) [CAS](#) [Google Scholar](#)

78. F.V. Gotor, R. Brieva, V. Gotor, J. Mol. Cat. B: Enzym. 40, 111 (2006)

[Article](#) [CAS](#) [Google Scholar](#)

79. E. Santaniello, S. Casati, P. Ciuffred, Curr. Org. Chem. 10, 1095 (2006)

[Article](#) [CAS](#) [Google Scholar](#)

80. B. Stauch, S.J. Fisher, M. Cianci, J. Lipid Res. 56, 2348 (2015)

[Article](#) [CAS](#) [PubMed](#) [PubMed Central](#) [Google Scholar](#)

81. J. Uppenberg, M. Trier Hansen, S. Patkar, T.A. Jones, Structure 2(4), 293 (1994)

[Article](#) [CAS](#) [PubMed](#) [Google Scholar](#)

82. A. Vinu, P. Kalita, V.V. Balasubramanian, H. Oveisi, T. Selvan, A. Mano, M.A. Chari, B.V.S. Reddy, Tetrahedron Lett. 50, 7132 (2009)

[Article](#) [CAS](#) [Google Scholar](#)

83. A.K. Bhattacharya, M. Mujahid, Syn. Commun. 43, 2583 (2013)

[Article](#) [CAS](#) [Google Scholar](#)

Acknowledgements

The authors are thankful to Late Professor D. B. Ingle for his invaluable discussions and guidance. The authors are also thankful to SAIF, Central Drug Research Institute (CDRI), Lucknow for spectral analysis.

Author information

Authors and Affiliations

Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, 431004, India

Anusaya S. Chavan, Manisha R. Bhosle, Sambhaji T. Dhumal & Ramrao A. Mane

Laboratory of Applied Microbiology, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India

Arun S. Kharat

Corresponding author

Correspondence to [Ramrao A. Mane](#).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

[Supplementary file1 \(DOCX 212 kb\)](#)

Rights and permissions

[Reprints and permissions](#)

About this article

Cite this article

Chavan, A.S., Kharat, A.S., Bhosle, M.R. *et al.* CAL-B accelerated novel synthetic protocols for 3,3'-arylidenebis-4-hydroxycoumarins and dimethyl ((substituted phenyl) (phenylamino)methyl) phosphonates. *Res Chem Intermed* 47, 4497–4512 (2021). <https://doi.org/10.1007/s11164-021-04535-2>

Received

02 March 2021

Accepted

05 July 2021

Published

19 July 2021

Issue Date

November 2021

DOI

<https://doi.org/10.1007/s11164-021-04535-2>

Share this article

Anyone you share the following link with will be able to read this content:

[Get shareable link](#)

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

[CAL-B](#)[Lipase](#)[Biocatalysts](#)[3,3-Arylidenebis-4-hydroxycoumarins](#)[Dimethyl \(\(substituted phenyl\) \(phenylamino\)methyl\) phosphonates](#)[Multicomponent condensation](#)